Systemic lupus erythematosus, discoid lupus erythematosus, and progressive systemic sclerosis

International Ophthalmology Clinics

Volumn 37, Issue 2, 1997, Pages 93-110

  Foster, C Stephen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE; METHYLPREDNISOLONE; PREDNISONE; TISSUE PLASMINOGEN ACTIVATOR;

DISCOID LUPUS ERYTHEMATOSUS; EPISCLERITIS; EYE DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; RETINOPATHY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

EYE DISEASES; HUMANS; LUPUS ERYTHEMATOSUS, DISCOID; LUPUS ERYTHEMATOSUS, SYSTEMIC; SCLERODERMA, SYSTEMIC;

EID: 0030746453     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-199703720-00008     Document Type: Review

References (76)

1. Rose E, Pillsbury DM. Acute disseminated lupus erythematosus - a systemic disease. Ann Intern Med 1939;12:951
2. Klemperer P, Pollack AD, Baehr G. Pathology of disseminated lupus erythematosus. Arch Pathol 1941;32:569
3. Hebra F, KaPosi M. On diseases of the skin including the exanthemata (W Tay, transl; C Hitlon, ed). London: The New Sydenham Society, 1874
4. Cazenave PLA, Chausit M. Du lupus (H. Frey, transl). Ann Malad Peau Syph 1852;4: 113
5. Hochberg MC. The epidemiology of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, eds. Dubois' lupus erythematosus, ed. Philadelphia: Lea & Febiger, 1993:49-57
6. Fessell WJ. SLE in the community: incidence, prevalence, outcome and first symptoms; the high prevalence in black women. Arch Intern Med 1974;134:1027
7. Johnson AE, Caval Canti FS, Gordon C, et al. Cross sectional analysis of the differences between patients with systemic lupus erythematosus in England, Brazil and Sweden. Lupus 1994;3:501
8. Skarsvag S. The importance of C4A Nal genes in Norwegian patients with systemic lupus erythematosus. Scand J Immunol 1995;42:572
9. Fisher GF, Pickl WF, Fae I, et al. Association between chronic cutaneous lupus erythematosus and HLA class II alleles. Hum Immunol 1994;41:280
10. Kotzin BL, Odel JR. Systemic lupus erythematous. In: Frank MM, Austen KF, Claman HN, Unanue ER, eds. Samter's immunologic diseases. Boston: Little, Brown, 1995: 667-697
11. Swaak AJ, Hintzen RQ, Huysen V, et al. Serum levels of soluble forms of T cell activation antigens CD 27 and CD 25 in systemic lupus erythematosus in relation to lymphocyte count and disease course. Clin Rheumatol 1995;14:293
12. H2 cytokine gene expression in systemic lupus erythematosus. Rev Invest Clin 1995;47:267
13. H2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol 1995;13: 339
14. Holcumbe RF, Baethge BA, Wolfe RE, et al. Correlation of serum interleukin-8 and cell surface lysosome-associated membrane protein expression with clinical disease activity in systemic lupus erythematosus. Lupus 1994;3:97
15. Li JS, Liu MF, Lei HY. Characterization of anti-endothelial cell antibodies in the patients with systemic lupus erythematosus: a potential marker for disease activity. Clin Immunol Immunopathol 1996;79:211
16. Tan EM, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271
17. Sontheimer RD, Gilliam JN. Systemic lupus erythematosus and the skin. In: Lahita RG, ed. Systemic lupus erythematosus, ed 2. New York: Churchill Livingstone, 1992:657-681
18. Pillat A. Ubar das Vorkommen von Choroiditis bei Lupus erythematodes. Graefes Arch Klin Exp Ophthalmol 1934;133:566
19. Gold DH, Morris DA, Henkind P. Ocular findings in SLE. Br J Ophthalmol 1972;56: 800
20. Spaeth GL. Corneal staining in systemic lupus erythematosus. N Engl J Med 1967;276: 1168
21. Zufferey P, Meyer OC, Bourgeois P, et al. Primary systemic Sjogren's syndrome preceding systemic lupus erythematosus: a retrospective study of four cases in cohort of 55 SS patients. Lupus 1995;4:23
22. Gold DH, Feiner L, Henkind P. Retinal arterial occlusive disease in systemic lupus erythematosus. Arch Ophthalmol 1977;95:1580
23. Koch JW, Small AL, Nawaisch JM, Coch FH. Severe occlusive bilateral retinal vasculitis within the scope of sero negative systemic lupus erythematosus. Klin Monatsbl Augenheilkd 1992;201:330-336
24. el-Asrar AM, Naddaf HO, al-Momen AK, et al. Systemic lupus erythematosus flareup manifesting as a cilioretinal artery occlusion. Lupus 1995;4:158
25. Hannouche D, Korobelnik JF, Cochereau I, et al. Systemic lupus erythematosus with choroidopathy and serous retinal detachment. Int Ophthalmol 1995;19:125
26. Benitez del Castillo JM, Castillo A, Fernandez-Cruz A, et al. Persistent choroidopathy in Systemic Lupus Erythematosus. Doc Ophthalmol 1994;88:175
27. Ahmadieh H, Roodpeyma S, Azarmina M, et al. Bilateral stimultaneous optic neuritis in childhood systemic lupus erythematosus. A case report. Neuro-Ophthalmology 1994; 14:84
28. Feldmann R, Salomon D, Saurat JH. The association of the anti-malarial, chloroquine, and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 1994;189:425
29. Leondike MR, Shattuck MA. Intravenous cyclophosphamide and lupus neuritis. J Intravenous Nurs 1993;16:23
30. Neuwelt CM, Lacks S, Kaye BR, et al. Role with intravenous cyclophosphamide in the treatment of severe neuro psychiatric systemic lupus erythematosus. Am J Med 1995; 98:32
31. Euler HH, Schroeder JO, Harten P, et al. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994;37:1784
32. Euler HH, Guillevin L. Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. An interim report of the Lupus Plasma Study Group. Ann Med Interne (Paris) 1994;145:296
33. Hanly JG, Hoang C, Zayed E. Immunomodulating effects of synchronized plasmapheresis and intravenous bolus cyclophosphamide in systemic lupus erythematosus. Lupus 1995;4:457
34. Bhimma R, Coovadia HM, Adhikari M. Improved outcome of systemic lupus erythematosus among children in Durban, South Africa. Ann Trop Paediatr 1994;14:119
35. Wilson K, Abeles M. A two year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1994;21:1674
36. Bottomly WW, Goodfield M. Methotrexate for the treatment of severe mucocutancous lupus erythematosus. Br J Dermatol 1995;133:311
37. Becker BN, Fuchs H, Hakim R. Intravenous immune golobulin in the treatment of patients with systemic lupus erythematosus and instage renal disease. Am Soc Nephrol 1995;5:1746
38. Foster RE, Lawder CY, Meisler DM, et al. An unusual ocular manifestation of discoid lupus erythematosus. Cleve Clin J Med 1994;61:232
39. Arbisar JL, Moschella SL. Clofazimine: a review of medical uses and mechanisms of action. J Am Acad Dermatol 1995;32:241
40. Callen JP. Treatment of cutaneous lesions in patients with lupus erythematosus. Dermatol Clin 1994;12:201
41. Curzio C. Discussioni anatomio-pratiche di un rare e stravagante morbo cutaneo in questo grande ospedale degi incurabili. Naples: G. DiSiome, 1753
42. Gintrac E. Note sur la sclerodermie. Rev Med Chir (Paris) 1847;2:263
43. Goetz RH. The pathology of progressive systemic sclerosis (generalized scleroderma) with special reference to changes in viscera. Clin Proc (Cape Town) 1945;4:337
44. Medsger TA. Epidemiology of systemic sclerosis. Clin Dermatol 1994;12:207
45. Arnett FC, Reveille JD, Goldstein R, et al. Auto antibodies to fibrillarin in systemic sclerosis and immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996;39: 1151
46. Arnett FC. HLA and auto immunity in scleroderma. Int Rev Ophthalmol 1995;12:107
47. Shero JH, et al. High titers of autoantibodies to topoisomerase I Sci-70 (in sera from scleroderma patients). Science 1986;231:737
48. Alonso-Ruiz A, et al. Toxic oil syndrome: a syndrome with features overlapping those of various forms of scleroderma. Semin Arthritis Rheum 1986;15:200
49. Belongia EA, et al. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med 1990;323:357
50. Vlachoyiannopolos PG, Boumba VA, Tzioufas AG. Auto antibodies to HMG-17 nucleosomal protein in patients with scleroderma. J Autoimmun 1994;7:193
51. Salmon-Her V, Serpier H. Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch Dermatol 1996;132: 802
52. Gurram M, Pahwa S, Frieri M. Augmented interleukin-6 secretion in collagen-stimulated peripheral blood mononuclear cells from patients with systemic sclerosis. Ann Allergy 1994;73:493
53. Higley H, Persichitte K, Chu S. et al. Immunocytochemical localization and in situ detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 1994;37:278
54. Southcott AM, Jones KP, Li D, et al. Interleukin-8. Differential expression in loan fibrosing alveolitis and systemic sclerosis. Am J Respir Crit Care Med 1995;151:1604
55. Patrick MR, Kurkham BW, Graham M, et al. Circulating interleukin-1 beta and soluble interleukin-2 receptor: evaluation as markers of disease activity in scleroderma. J Rheumatol 1995;22:654
56. Heickendorff L, Zachariae H, Bjerring P, et al. The use of serologic markers for collagen synthesis and degradation in systemic sclerosis. J Am Acad Dermatol 1995;32:584
57. Kraling BM, Maul GG, Jimenez SA. Mononuclear cell infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Path Biol 1995;63:48
58. Eckes B, Mauch C, Huppe G, et al. Differential regulation of transcription and transcription and transcript stability of pro-alpha 1 collagen and fibronectin in activated fibroblasts derived from patients with systemic scleroderma. Biochem J 1996;315:249
59. Sgonc R, Gruschwitz MS, Deitrich H, et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996;98:785
60. Greenan DM, Forrester J. Involvement of the eye in SLE and scleroderma. Ann Rheum Dis 1977;36:152
61. Ashton N, et al. Retinopathy due to progressive systemic sclerosis. J Pathol Bacteriol 1968;96:359
62. Farkes TG, Sylvester V, Archer D. The choroidopathy of progressive systemic sclerosis (scleroderma). Am J Ophthalmol 1972;74:875
63. Alarcon-Segovia D, et al. Sjogren's syndrome and progressive systemic sclerosis (scleroderma). Am J Med 1974;57:78
64. Kirkham TH. Scleroderma and Sjogren's syndrome. Br J Ophthalmol 1969;53:131
65. Stucci CA, Geiser JD. Manifestations oculares de la sclerodermie generalisee (points communs avec le syndrome de Sjogren). Doc Ophthalmol 1967;22:72
66. Horan EC. Ophthalmic manifestations of progressive systemic sclerosis. Br J Ophthalmol 1969;53:388
67. West RH, Barnett AJ. Ocular involvement in scleroderma. Br J Ophthalmol 1979;63: 845
68. Arnett FC, Michels RG. Inflammatory ocular myopathy in systemic sclerosis (scleroderma). Arch Intern Med 1973;132:740
69. Manschot WA. Generalized scleroderma with ocular symptoms. Ophthalmologica 1965; 149:131
70. McWhae JA, Andrews DM. Transient corneal opacification induced by cold in Raynaud's disease. Ophthalmology 1991;98:666
71. Polisson RP, Gilkeson GS, Pyun AH, et al. A multi-center trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin-2 receptor levels. J Rheumatol 1996;23:654
72. van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a twenty-four week randomized double-blind trial followed by a twenty-four week observation trial. Br J Rheumatol 1996; 35:364
73. Wilson D, Edworthy SM, Hart DA, et al. The safety and efficacy of low-close tissue plasminogen activator in the treatment of sclerosis. J Dermatol 1995;22:637
74. Pai BS, Srinivas CR, Sabaitha L, et al. Efficacy of dethomexadone pulse therapy and progressive systemic sclerosis. Int J Dermatol 1995;34:726
75. Akesson A, Scheja A, Lundin A. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994;37:729
76. Dau PC, Callahan JP. Immune modulation during the treatment of systemic sclerosis with plasmapheresis and immunosuppressive drugs. Clin Immunol Immunopathol 1994;70:159